Literature DB >> 10092675

Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.

L Narhi1, S J Wood, S Steavenson, Y Jiang, G M Wu, D Anafi, S A Kaufman, F Martin, K Sitney, P Denis, J C Louis, J Wypych, A L Biere, M Citron.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder that is pathologically characterized by the presence of intracytoplasmic Lewy bodies, the major component of which are filaments consisting of alpha-synuclein. Two recently identified point mutations in alpha-synuclein are the only known genetic causes of PD, but their pathogenic mechanism is not understood. Here we show that both wild type and mutant alpha-synuclein form insoluble fibrillar aggregates with antiparallel beta-sheet structure upon incubation at physiological temperature in vitro. Importantly, aggregate formation is accelerated by both PD-linked mutations. Under the experimental conditions, the lag time for the formation of precipitable aggregates is about 280 h for the wild type protein, 180 h for the A30P mutant, and only 100 h for the A53T mutant protein. These data suggest that the formation of alpha-synuclein aggregates could be a critical step in PD pathogenesis, which is accelerated by the PD-linked mutations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092675     DOI: 10.1074/jbc.274.14.9843

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  232 in total

1.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation.

Authors:  L C Serpell; J Berriman; R Jakes; M Goedert; R A Crowther
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

Review 2.  Protein aggregates and dementia: is there a common toxicity?

Authors:  S Lovestone; D M McLoughlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

3.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.

Authors:  P J Kahle; M Neumann; L Ozmen; V Müller; S Odoy; N Okamoto; H Jacobsen; T Iwatsubo; J Q Trojanowski; H Takahashi; K Wakabayashi; N Bogdanovic; P Riederer; H A Kretzschmar; C Haass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

4.  Neuropathology in mice expressing human alpha-synuclein.

Authors:  H van der Putten; K H Wiederhold; A Probst; S Barbieri; C Mistl; S Danner; S Kauffmann; K Hofele; W P Spooren; M A Ruegg; S Lin; P Caroni; B Sommer; M Tolnay; G Bilbe
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

5.  alpha-synuclein promotes mitochondrial deficit and oxidative stress.

Authors:  L J Hsu; Y Sagara; A Arroyo; E Rockenstein; A Sisk; M Mallory; J Wong; T Takenouchi; M Hashimoto; E Masliah
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

6.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Authors:  Michael R Sierks; Gaurav Chatterjee; Claire McGraw; Srinath Kasturirangan; Philip Schulz; Shalini Prasad
Journal:  Integr Biol (Camb)       Date:  2011-11-10       Impact factor: 2.192

7.  Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro.

Authors:  John Goers; Vladimir N Uversky; Anthony L Fink
Journal:  Protein Sci       Date:  2003-04       Impact factor: 6.725

8.  Distinct hydration properties of wild-type and familial point mutant A53T of α-synuclein associated with Parkinson's disease.

Authors:  E Hazy; M Bokor; L Kalmar; A Gelencser; P Kamasa; K-H Han; K Tompa; P Tompa
Journal:  Biophys J       Date:  2011-11-01       Impact factor: 4.033

Review 9.  Folding and misfolding of alpha-synuclein on membranes.

Authors:  Igor Dikiy; David Eliezer
Journal:  Biochim Biophys Acta       Date:  2011-09-16

Review 10.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.